ArticleCardio-oncology (London, England)2026
Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in chemotherapy-naïve patients with mCRPC treated with ENZA or ABI and to provide outcome data based on CV disease (CVD) history using the US Medicare database.
methodsChemotherapy-naïve patients with mCRPC (≥ 65 years) who initiated ENZA or ABI (September 2014 − May 2017) were included. The primary endpoint was a 4-point major adverse CV event (MACE; a composite of acute myocardial infarction, stroke, unstable angina/revascularization, and heart failure). Atrial fibrillation, venous thromboembolism, and all-cause death were also analyzed. Further, the risk of adverse CV outcomes was compared between ENZA- and ABI-treated cohorts (overall population and by CVD-risk subgroup). Sensitivity analysis was performed using a 5-point MACE (4-point MACE plus CV-related death) as the endpoint.
resultsOf 6319 patients (ENZA: 2934; ABI: 3385), 2913 propensity score-matched patients were included from each group (prior CVD: 76%). ABI was associated with a significantly higher risk of 4-point MACE (hazard ratio [HR]: 1.12; 95% confidence interval [CI]: 1.02–1.24; P = 0.028), unstable angina/revascularization (HR: 1.13; 95% CI: 1.01–1.26; P = 0.041), atrial fibrillation (HR: 1.73; 95% CI: 1.31–2.29; P < 0.001), venous thromboembolism (HR: 1.37; 95% CI: 1.02–1.85; P = 0.037), and all-cause death (HR: 1.13; 95% CI: 1.07–1.19; P < 0.001) versus ENZA. In the sensitivity analyses, these results were confined to the subgroup of patients with a history of CVD.
conclusionsABI-treated patients with mCRPC had a higher risk of developing composite 4-point MACE and other CV events than ENZA-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.